Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$680M |
| 2 |
Microsoft
MSFT
|
+$506M |
| 3 |
UnitedHealth
UNH
|
+$393M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$381M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$348M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.24B |
| 2 |
Tesla
TSLA
|
+$450M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$444M |
| 4 |
TSMC
TSM
|
+$432M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$371M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 1.79% |
| 2 | Consumer Discretionary | 0.82% |
| 3 | Financials | 0.79% |
| 4 | Healthcare | 0.66% |
| 5 | Industrials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
12126
AN2 Therapeutics
ANTX
$218M
| $48K | ﹤0.01% |
+45,320
| New | +$54K |
|
12127
PMV Pharmaceuticals
PMVP
$69.5M
| $47.4K | ﹤0.01% |
+44,758
| New | +$43.9K |
|
12128
PUT
American Battery Technology Co
ABAT
$355M
| $47.1K | ﹤0.01% |
29,100
+14,200
| +95% | +$18.4K |
|
12129
Cardio Diagnostics
CDIO
$5.45M
| $47K | ﹤0.01% |
+13,060
| New | +$97.7K |
|
12130
PepGen
PEPG
$217M
| $47K | ﹤0.01% |
42,305
-33,303
| -44% | -$47.1K |
|
12131
CALL
Eledon Pharmaceuticals
ELDN
$273M
| $46.9K | ﹤0.01% |
+17,300
| New | +$51.9K |
|
12132
KLX Energy Services
KLXE
$34.3M
| $46.8K | ﹤0.01% |
25,015
-39,296
| -61% | -$81.7K |
|
|
HOOK
12133
DELISTED
HOOKIPA Pharma
HOOK
| $46.8K | ﹤0.01% |
37,265
+18,044
| +94% | +$22.3K |
|
|
CARV
12134
DELISTED
Carver Bancorp
CARV
| $46.7K | ﹤0.01% |
+27,016
| New | +$39.4K |
|
12135
NeoVolta
NEOV
$198M
| $46.7K | ﹤0.01% |
14,141
-659
| -4% | -$1.89K |
|
|
TERN
12136
CALL
DELISTED
Terns Pharmaceuticals
TERN
| $46.3K | ﹤0.01% |
12,400
-113,300
| -90% | -$354K |
|
12137
INmune Bio
INMB
$68.3M
| $46.1K | ﹤0.01% |
19,945
-20,350
| -51% | -$149K |
|
|
KWM
12138
K Wave Media Ltd
KWM
$4.16M
| $46K | ﹤0.01% |
+453
| New | +$44.4K |
|
|
NXDR
12139
PUT
Nextdoor Holdings
NXDR
$894M
| $45.8K | ﹤0.01% |
27,600
-25,800
| -48% | -$38.9K |
|
12140
Sono-Tek
SOTK
$81.6M
| $45.7K | ﹤0.01% |
12,021
-785
| -6% | -$2.98K |
|
12141
PUT
Workhorse Group
WKHS
$32.9M
| $45.5K | ﹤0.01% |
3,450
-5,225
| -60% | -$67.8K |
|
|
ZJYL
12142
Jin Medical International
ZJYL
$204M
| $45.3K | ﹤0.01% |
3,518
+400
| +13% | +$6.09K |
|
|
DMRA
12143
Damora Therapeutics
DMRA
$1.89B
| $45.2K | ﹤0.01% |
13,602
+2,880
| +27% | +$8.52K |
|
12144
CALL
CarParts.com
PRTS
$48.4M
| $45K | ﹤0.01% |
+6,080
| New | +$52K |
|
12145
TOP Financial Group
TOP
$1.9B
| $44.8K | ﹤0.01% |
7,293
+4,660
| +177% | +$28.4K |
|
|
CAPT
12146
CALL
DELISTED
Captivision
CAPT
| $44.7K | ﹤0.01% |
39,200
+11,300
| +41% | +$8.27K |
|
12147
Flux Power
FLUX
$13.8M
| $44.1K | ﹤0.01% |
29,198
-9,397
| -24% | -$15.3K |
|
|
CAPT
12148
PUT
DELISTED
Captivision
CAPT
| $44K | ﹤0.01% |
38,600
-40,300
| -51% | -$29.5K |
|
12149
CALL
Design Therapeutics
DSGN
$984M
| $43.8K | ﹤0.01% |
+13,000
| New | +$48.6K |
|
|
ESPR
12150
CALL
DELISTED
Esperion Therapeutics
ESPR
| $43K | ﹤0.01% |
43,900
-1,400
| -3% | -$1.4K |
|
Similar funds
Jeff Yass's Q2 2025 Portfolio in Review
As of Q2 2025, Jeff Yass held 14,080 positions worth $720B, up 23% from $586B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Jeff Yass deployed $32.3B of net new capital in Q2 2025, opening 1,720 new positions and adding to 5,716 existing holdings. Its largest new stake was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M.
By sector, the portfolio is most concentrated in Technology at 1.8% of assets, up from 1.6% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $5.24B trimmed.
- Jeff Yass's largest Q2 2025 buy was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M.
- Jeff Yass added most to Apple in Q2 2025, an estimated $680M increase.
- Jeff Yass's biggest Q2 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.24B.
- Jeff Yass fully exited Vanguard Intermediate-Term Bond ETF in Q2 2025, selling an estimated $61.8M.
- Jeff Yass's ten largest holdings make up 26% of its $720B portfolio in Q2 2025.
- Jeff Yass opened 1,720 new positions and closed 1,538 in Q2 2025.
- Jeff Yass's portfolio value rose 23% quarter-over-quarter to $720B.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.